Clinical features of patients with diagnosis of COVID-19 confirmed by rhinopharyngeal swab and chest X-ray
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
| Diagnosis | Takayasu arteritis | Takayasu arteritis | Cranial GCA | Cranial GCA |
| Age, years | 38 | 33 | 79 | 79 |
| Sex | Female | Female | Male | Male |
| Comorbidities | Hypertension | Smoking | Hypertension | CAD, CKD |
| Disease status at last visit | Remission | Remission | Remission | Remission |
| Disease duration, months | 99 | 111 | 5 | 13 |
| Prednisone, mg | 5 | 5 | 17.5 | 7.5 |
| csDMARD (duration, months) | MTX 20 mg (82) | MTX 20 mg (105) | – | – |
| bDMARD (duration, months) | IFX 10 mg/kg (75) | ADA 40 mg (27) | – | – |
| Contact with COVID-19+ | No | Yes | Yes | No |
| Rhinopharyngeal swab | Positive | Positive | Positive | Positive |
| Chest X-ray findings | Pneumonia | Pneumonia | Pneumonia | Pneumonia |
| Chest CT findings | Not done | Not done | Interstitial pneumonia | Interstitial pneumonia |
| Hospital admission | No | No | Yes* | Yes |
| CRP levels (mg/L) | ||||
| On admission | – | – | 42 mg/L | 51 mg/L |
| At discharge | – | – | 8 mg/L | 11 mg/L |
| Therapy | None | None | HCQ 400 mg daily | HCQ 400 mg daily |
| Length of hospitalisation | – | – | 8 days | 19 days |
| Outcome | Full recovery | Full recovery | Full recovery | Full recovery |
*COVID-19 developed during hospital admission for a different medical reason.
bDMARD, biological disease-modifying antirheumatic drug; CAD, coronary artery disease; CKD, chronic kidney disease; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; GCA, giant cell arteritis; HCQ, hydroxychloroquine; IFX, infliximab; MTX, methotrexate.